Mostrar el registro sencillo del ítem
| dc.contributor.author | Diaz-Beya, M | |
| dc.contributor.author | Pratcorona, M | |
| dc.contributor.author | Nomdedeu, M | |
| dc.contributor.author | Risueno, R-M | |
| dc.contributor.author | Brunet, S | |
| dc.contributor.author | Nomdedeu, J | |
| dc.contributor.author | Hoyos, M | |
| dc.contributor.author | Sierra, J | |
| dc.contributor.author | Cordeiro, A | |
| dc.contributor.author | Castellano, J-J | |
| dc.contributor.author | Monzo, M | |
| dc.contributor.author | Navarro, A | |
| dc.contributor.author | Tormo, M | |
| dc.contributor.author | Escoda, L | |
| dc.contributor.author | Ribera, J-M | |
| dc.contributor.author | Arnan, M | |
| dc.contributor.author | Heras-Fernando, Inmaculada | |
| dc.contributor.author | Gallardo, D | |
| dc.contributor.author | Bargay, J | |
| dc.contributor.author | Queipo-de-Llano, M-P | |
| dc.contributor.author | Salamero, O | |
| dc.contributor.author | Marti, J-M | |
| dc.contributor.author | Sampol, A | |
| dc.contributor.author | Pedro, C | |
| dc.contributor.author | Esteve, J | |
| dc.date.accessioned | 2026-10-21T06:12:26Z | |
| dc.date.available | 2026-10-21T06:12:26Z | |
| dc.date.issued | 2015-10-02 | |
| dc.identifier.citation | Díaz-Beyá M, Brunet S, Nomdedéu J, Cordeiro A, Tormo M, Escoda L, et al. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia. Blood Cancer Journal. 2 de octubre de 2015;5(10):e352-e352. doi:10.1038/bcj.2015.76 | |
| dc.identifier.issn | 2044-5385 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/28760 | |
| dc.description.abstract | Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by cytogenetics and molecular profiling. In elderly patients (?60 years) with normal karyotype AML miR-3151 have been identified as a prognostic factor. However, miR-3151 prognostic value has not been examined in younger AML patients. In the present work, we have studied miR-3151 alone and in combination with BAALC, its host gene, in a cohort of 181 younger intermediate-risk AML (IR-AML) patients. Patients with higher expression of miR-3151 had shorter overall survival (P=0.0025), shorter leukemia-free survival (P=0.026) and higher cumulative incidence of relapse (P=0.082). Moreover, in the multivariate analysis miR-3151 emerged as independent prognostic marker in both the overall series and within the unfavorable molecular prognostic category. Interestingly, the combined determination of both miR-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers (P=0.003). In addition, we studied the microRNA expression profile associated with miR-3151 identifying a six-microRNA signature. In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML. | |
| dc.language.iso | eng | |
| dc.rights | Atribución/Reconocimiento 4.0 Internacional | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/deed.es | * |
| dc.subject.mesh | Adolescent | |
| dc.subject.mesh | Adult | |
| dc.subject.mesh | Aged | |
| dc.subject.mesh | Biomarkers, Tumor/genetics | |
| dc.subject.mesh | Cytogenetic Analysis | |
| dc.subject.mesh | Disease-Free Survival | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Kaplan-Meier Estimate | |
| dc.subject.mesh | Leukemia, Myeloid, Acute/genetics/mortality | |
| dc.subject.mesh | Male | |
| dc.subject.mesh | MicroRNAs/genetics | |
| dc.subject.mesh | Middle Aged | |
| dc.subject.mesh | Neoplasm Proteins/genetics | |
| dc.subject.mesh | Prognosis | |
| dc.subject.mesh | Proportional Hazards Models | |
| dc.subject.mesh | Risk Factors | |
| dc.subject.mesh | Transcriptome | |
| dc.subject.mesh | Young Adult | |
| dc.title | The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 26430723 | |
| dc.relation.publisherversion | https://www.nature.com/articles/bcj201576 | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dc.identifier.doi | 10.1038/bcj.2015.76 | |
| dc.journal.title | Blood Cancer Journal |